Schond Greenway

Schond Greenway

Nessuna posizione attualmente
54 anni
Health Technology
Consumer Services
Finance

Profilo

Schond L.
Greenway
worked at Halozyme Therapeutics, Inc. as Executive Director-Strategy & IR from 2013 to 2016.
Worked at Mesoblast Ltd. as VP & Global Head-Investor Relations from 2016 to 2021.
Worked at Avalo Therapeutics, Inc. as Chief Financial Officer & Treasurer from 2021 to 2022.
Worked at Definium Therapeutics, Inc. as Chief Financial Officer from 2022 to 2024.
Also held positions at DURECT Corp.
as VP-Investor Relations & Strategic Planning and at Barclays Capital, Inc. as Vice President-Healthcare.
Education includes undergraduate studies at Florida A&M University and an MBA from the University of Virginia Darden School of Business.

Precedenti posizioni note di Schond Greenway

SocietàPosizioneFine
DEFINIUM THERAPEUTICS, INC. Direttore Finanziario/CFO 03/05/2024
AVALO THERAPEUTICS, INC. Direttore Finanziario/CFO 14/02/2022
MESOBLAST LIMITED Contatto Relazioni con gli Investitori 01/02/2021
HALOZYME THERAPEUTICS, INC. Contatto Relazioni con gli Investitori 01/01/2016
DURECT Public Communications Contact -
Vedi nel dettaglio l'esperienza di Schond Greenway

Formazione di Schond Greenway

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Relazioni

54

Relazioni di 1° grado

8

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Società collegate

Aziende private8

Health Technology

Health Technology

Finance

Consumer Services

Health Technology

Health Technology

Consumer Services

Health Technology

  1. Mercati
  2. Insiders
  3. Schond Greenway